Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

Wu, Lian‐Ming; Hu, Jiani; Gu, Heng; Hua, Jia; Chen, Jie; Xu, Jianrong

doi:10.1007/s10549-012-2033-5

Cited by 98 publications

(64 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis of several studies has shown that this effect of increased ADC value is consistent with pathological response, with sensitivity of 93% and a specificity of 82%. Moreover, the LR were significant [LR+ = 5.09 and LR− = 0.090 (29,51)]. This is consistent with our data in patients with operable disease (Figure 3).…”

Section: Multiparametric and Multimodality Imaging Of Treatment Resposupporting

confidence: 91%

“…This phenomenon has been demonstrated in several studies to differentiate between benign and malignant lesions (26,27) and metastatic lesions (28). Moreover, recent reports have confirmed that the ADC is a valuable radiological marker of treatment response in breast cancer (29,30). Thus, integrating DWI in a breast imaging treatment protocol is very important.…”

Section: Diffusion-weighted Imagingmentioning

confidence: 82%

“…Several studies have offered preliminary evidence that single-modality approaches, either MRI or PET/CT, provide potentially valuable information that can be used in the characterization of treatment response using the pathological response as an endpoint. For example, using DCE-MRI as a marker of the vascularity of the tumor and early treatment response, a recent meta-analysis showed that DCE metrics had a sensitivity of 68% and a specificity of 91%, with likelihood ratios (LR) of LR+ (7.48) and LR− (0.36) (29). Similar results were shown in another study, where DCE-MRI tumor volume had a response prediction rate of greater than 65%, and the rate of prediction with K trans rate was 85% (22,50).…”

Section: Multiparametric and Multimodality Imaging Of Treatment Respomentioning

confidence: 99%

See 2 more Smart Citations

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

et al. 2015

View full text Add to dashboard Cite

Breast cancer is the second leading cause of cancer death among US women, and the chance of a woman developing breast cancer sometime during her lifetime is one in eight. Early detection and diagnosis to allow appropriate locoregional and systemic treatment are key to improve the odds of surviving its diagnosis. Emerging data also suggest that different breast cancer subtypes (phenotypes) may respond differently to available adjuvant therapies. There is a growing understanding that not all patients benefit equally from systemic therapies, and therapeutic approaches are being increasingly personalized based on predictive biomarkers of clinical benefit. Optimal use of established and novel radiological imaging methods, such as magnetic resonance imaging and positron emission tomography, which have different biophysical mechanisms can simultaneously identify key functional parameters. These methods provide unique multiparametric radiological signatures of breast cancer, that will improve the accuracy of early diagnosis, help select appropriate therapies for early stage disease, and allow early assessment of therapeutic benefit.

show abstract

Section: Multiparametric and Multimodality Imaging Of Treatment Resposupporting

confidence: 91%

Section: Diffusion-weighted Imagingmentioning

confidence: 82%

Section: Multiparametric and Multimodality Imaging Of Treatment Respomentioning

confidence: 99%

See 1 more Smart Citation

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…They found that sensitivity and specificity for contrast-enhanced MRI was 0.68 (95% confidence interval (CI) 0.57-0.77) and 0.91 (95% CI 0.87-0.94), respectively. For DWI, sensitivity and specificity were 0.93 (95% CI 0.82-0.97) and 0.82 (95% CI 0.70-0.90), respectively [44]. The minor variations in these observations can be explained by the minor differences in inclusion and exclusion criteria that were applied in their reviews.…”

Section: Pathologic Complete Response (Pcr)mentioning

confidence: 93%

Response monitoring of breast cancer patientsreceiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge

Lobbes

Prevos²,

Smidt³

2012

J Cancer Ther Res

View full text Add to dashboard Cite

show abstract

“…DWI je osjetljiva na promjene u difuziji vode u ćelijskom i vanćelijskom prostoru, što se kvantifikuje koeficijentom difuzije vode (Apparent diffusion coefficient -ADC), i mjera je celularnosti lezije. Maligne lezije dojke uglavnom imaju niže vrijednosti ADC u odnosu na benigne lezije, kao odraz ograničene difuzija vode usljed povećane ćelijske gustoće u malignim lezijama [2,[21][22][23].…”

Section: Mjerenje Difuzije Pomoću Magnetne Rezonance (Diffusion-weighunclassified

Magnetna rezonanca dojke

Ristić

Joković

Ćuk

2015

Biomedicinska istraž.

View full text Add to dashboard Cite

Kratak sadržajKarcinom dojke je najčešći maligni tumor u ženskoj populaciji. Mamografija i ultrazvuk su osnovni vizuelizacioni modaliteti za dijagnostiku karcinoma dojke, a istraživanja su pokazala da magnetna rezonanca ima veću osjetljivost u njegovoj detekciji u odnosu na njih. Magnetna rezonanca dojke je uključena u dijagnostički algoritam karcinoma dojke, mada još uvijek nakon mamografije i ultrazvuka i u korelaciji s njima. Ipak, niska specifičnost magnetne rezonance dojke i visoka cijena njenog izvođenja ograničavaju njenu širu upotrebu.U radu su prikazane savremene mogućnosti i značaj primjene magnetne rezonance u dijagnostici, skriningu, određivanju raširenosti bolesti karcinoma dojke, kao i postterapijskom praćenju ovih bolesnica. Magnetna rezonanca dojke se odlikuje velikom osjeljivošću ali slabijom specifičnošću koja se povećava primjenom kontrastnih sredstava (dinamička magnetna rezonanca dojke). Jedna od njenih prednosti je što omogućava i izvođenje ciljanih biopsija.Ključne riječi: karcinom dojke, magnetna rezonanca, mamografija, ultrazvuk UvodU detekciji karcinoma dojke uz anamnezu i klinički pregled dojke, aksilaranih, supraklavikularnih i parasternalnih žlijezda mogu da se koriste različite dijagnostičke vizuelizacione metode, a to su ultrazvuk (ehomamografija, u novije vrijeme često dopunjena elastografijom), mamografija (danas se preporučuje digitalna), magnetna rezonanca dojke (magnetna rezonantna mamografija -MRM). Mamografija i ultrazvuk dojke su osnovne metode vizuelizacije za dijagnostiku karcinoma dojke. Od rezultata ovih pretraga zavisi odluka o izvođenju analize tkiva [1].MRM predstavlja metod vizuelizacije koji se koristi u skriningu i dijagnozi karcinoma dojke, obično kao dopuna mamografije i/ili ultrazvučne dijagnostike. Bazira se na procjeni morfologije uočenih lezija dojke, bradavice, kože, zida grudnog koša, pazuha, supraklavikularnog i parasternealnog prostora, kao i perfuzije tkiva dojke nakon primjene kontrastnog sredstva na bazi gadolinijuma sa praćenjem dinamike njegove tkivne akvizicije (dynamic contrast enhancement -DCE MRI) [2][3][4][5][6].

show abstract

Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

Cited by 98 publications

References 53 publications

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment

Response monitoring of breast cancer patientsreceiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge

Magnetna rezonanca dojke

Contact Info

Product

Resources

About